|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
0.10/--
|
企业价值
50.10M
|
资产负债 |
每股账面净值
4.27
|
现金流量 |
现金流量率
--
|
损益表 |
收益
279.00K
|
每股收益
0.01
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/06/18 07:08 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. |